FDA Classifies Medtronic Voluntary February Recall For Intrepid™ Intervertebral Body Fusion Device As Class II
Medtronic, Inc. (NYSE: MDT) announced that the U.S. Food and Drug Administration (FDA) has classified its voluntary recall action of the Intrepid™ Intervertebral Body Fusion Device as a Class II recall. Medtronic initiated a voluntary recall of the product on February 6, 2009, and communicated the risk to physicians and hospitals. As of the date of this news release, all unused product has been retrieved and Medtronic has received confirmation of notification from all affected physicians and hospitals.
Oncology
Pages: 1 [2]
Afinitor(R) Phase II Data Show Positive Results For Patients With Multiple Types Of Lymphoma, Leading To Phase III Trial
from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group"s continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time-equivalent associates and operate in more than 140 countries around the world. References 1. Thomas E. Witzig et al. A Phase II Trial of the Oral mTor Inhibitor Everolimus in Relapsed Non-Hodgkin"s Lymphoma (NHL) and Hodgkin"s Disease (HD). EHA 14th Congress. Berlin, Germany 2. National Cancer Institute. General Information about Non-Hodgkin Lymphoma. 3. National Cancer Institute. What You Need to Know About Non-Hodgkin"s Lymphoma. What is Non-Hodgkin"s Lymphoma? 4. National Cancer Institute. General Information on Non-Hodgkin"s. 5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin"s Lymphoma. 6. X Zhang et al. Serum diagnosis of diffuse large B-cell lymphomas and further identification of response to therapy using SELDI-TOF-MS and tree analysis patterning. BMC Cancer 2007, 7:235 7. American Cancer Society. What Is Hodgkin"s Disease? 8. National Cancer Institute. General Information About Adult Non-Hodgkin"sLymphoma. 9. D. Max Parkin, MD et al. Global Cancer Statistics 2002. American Cancer Society. NovartisPages: 1 [2]